A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
|Articles|November 19, 2021
Pharmacy Clinical Pearl of the Day: Hodgkin Lymphoma
Author(s)Saro Arakelians, PharmD
Hodgkin lymphoma is most common in people between 20 and 40 years of age and those over 55 years of age.
Advertisement
Clinical Pearl of the Day: Hodgkin Lymphoma
Hodgkin lymphoma is a cancer of the lymphatic system, which is part of the immune system.
Insight:
- Hodgkin lymphoma may affect people of any age but is most common in people between 20 and 40 years of age and those over 55 years of age.
- Symptoms include painless swelling of lymph nodes in the neck, armpits or groin, persistent fatigue, fever, night sweats, unexplained weight loss, severe itching, and increased sensitivity to alcohol or pain.
- Subtypes of classical Hodgkin lymphoma include nodular sclerosis Hodgkin lymphoma, mixed cellularity Hodgkin lymphoma, lymphocyte-depleted Hodgkin lymphoma, and lymphocyte-rich Hodgkin lymphoma.
- Risk factors include age between 15 to 30 years and over 55 years, family history of lymphoma, being male, and past Epstein-Barr infection
- Diagnosis includes physical exam, blood tests, imaging tests, removing the lymph node for testing and removing a sample of bone marrow for testing
- Treatment includes chemotherapy, radiation therapy and bone marrow transplant
- Chemotherapy options include:
Sources:
Advertisement
Related to this article
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5